Last reviewed · How we verify
OP-724
At a glance
| Generic name | OP-724 |
|---|---|
| Also known as | CBP-beta-catenin inhibitor, PRI-724 (former name) |
| Sponsor | Kiminori Kimura, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201) (PHASE2)
- Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia. (PHASE1)
- A Follow-up Evaluation Study of PRI-724-1101
- An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis (PHASE1)
- Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OP-724 CI brief — competitive landscape report
- OP-724 updates RSS · CI watch RSS
- Kiminori Kimura, MD portfolio CI